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The systems-level characterization of drug-target associations in myocardial infarction (MI) has not been
reported to date. We report a computational approach that combines different sources of drug and protein
interaction information to assemble the myocardial infarction drug-target interactome network
(My-DTome). My-DTome comprises approved and other drugs interlinked in a single, highly-connected
networkwithmodularorganization.Weshowthatapprovedandotherdrugsmaybothbehighlyconnected
and represent network bottlenecks. This highlights influential roles for such drugs on seemingly unrelated
targets and pathways via direct and indirect interactions. My-DTome modules are associated with relevant
molecular processes and pathways. We find evidence that these modules may be regulated by microRNAs
with potential therapeutic roles in MI. Different drugs can jointly impact a module. We provide systemic
insights into cardiovascular effects of non-cardiovascular drugs. My-DTome provides the basis for an
alternative approach to investigate new targets and multidrug treatment in MI.
M
yocardial infarction (MI) and its associated complications represent a major cause of death and health-
carecostsintheworld.Despitesignificantinterventionaladvances,treatmentoptionsrelyonarelatively
small number of approved drugs, and little is known of underlying interactions between these com-
pounds, targets and complex biological pathways. Moreover, most of these drugs were developed without a deep
understanding of their systems-level molecular activity.
Targets and drugs do not interact in isolation and unintended interactions may give rise to undesirable
effectiveness and even safety effects on patients. We aim to enhance our understanding of the relationships
betweenknownandputativetherapeuticcompoundsandtargetsusedtotreatMIpatients.Weintegratedifferent
types of information resources about drugs and proteins by means of a biological network framework to: a. offer
an annotated research resource for future investigations, b. investigate biologically meaningful properties of this
drug-target interaction network, and c. establish novel associations between drugs, targets and MI-related
molecular mechanisms.
Previous research has shown the usefulness of drug-target interaction networks to find inter-disease associa-
tions, repurpose drugs and predict side effects
1–6.However, drug-target interaction network approaches have not
been specifically explored in the area of cardiovascular research. Moreover, the majority of published methods
from other clinical settings tend to be biased toward approved drugs and their known targets
3,6,7. This limits the
utility of drug-target interaction networks with regard to their capacity to discover new knowledge of potential
targetsandoff-targetassociationsataproteome-orsystems-level.Thisisparticularlyevidentinclinicaldomains
with relatively small numbers of approved drugs and their interacting targets, as is the case of MI. Furthermore,
there is a lack of investigations specific to the MI domain.
In this research we generate and analyze a MI drug-target interactome network (My-DTome), which extends
beyond the incorporation of approved drugs and primary targets. My-DTome integrates information about
clinically relevant drug-drug, drug-target and protein-protein interactions, including those without well-estab-
lishedassociationswithMI.Theresultingnetworklaysthefoundationforamorecomprehensivevisualizationof
the drug-target interaction landscape. This offers new opportunities for understanding the biological basis of
treatmentefficacy,safetyandpatientmanagement.Wehavedevelopedanetwork-driven,integratedapproachto
assemble and analyze My-DTome.
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My-DTome generation. To generate My-DTome, first we
incorporated all drugs approved by the European Medicines
Agency (EMA) (http://www.ema.europa.eu) for use in MI. This
drug set was expanded by retrieving other compounds related to
MI, as annotated by the Pharmacogenomics Knowledge Base
(PharmGKB)
8. These two sets of MI-related drugs constitute our
set of seed drugs. This set was used to query drug-drug interactions
storedinDrugBank
9.Next,weobtainedthetargetsfortheseeddrugs
and their interacting drugs. This was followed by the extraction of
validated human protein-protein interactions (PPI) for the resulting
set of targets from different high-quality, complementary databases.
The union of the drug-drug, drug-target and target-protein
interactions resulted in My-DTome. In its graphical network
format, nodes represent either compounds or proteins and edges
encode either drug-drug, drug-protein or protein-protein
interactions. Fig. 1 depicts My-DTome network development and
analysis phases.
My-DTome: A novel drug-target network in MI. My-DTome
network consists of 2097 nodes and 3958 edges, with a highly
connected network component comprising 2095 nodes and 3957
edges. We focused on the latter for subsequent analyses
(Supporting Information, Dataset 1). Among the edges, there are
1125 drug-target interactions. Fig. 2A shows a global view of My-
DTome with colour-coded nodes: seed drugs (green), other drugs
(blue), drug targets (orange) and other interacting proteins (grey).
The 38 seed drugs (only 10 EMA-approved) display different
numbers of interactions with other drugs (715 in total, mean value:
18.82) (Fig. 2B). The anticoagulant warfarin exhibits the highest
number of drug interactions. Seed and other drugs also display a
rich landscape of interacting targets, whose numbers do not appear
to be biased toward seed drugs (Fig. 2C). Among the 38 seed drugs,
verapamil has the highest number of targets (17 targets). Clozapine
(26 targets) and triazolam (20 targets) are examples of highly
connected drugs that are not labeled as seed drugs. The former is
used to treat psychiatric disorders, while the latter is a sedative. The
averagenumberofdrugtargetsperseedandotherdrugswas2.45and
3.12 respectively. This further indicates that My-DTome encodes a
drug-target space that is not biased toward approved drugs. The
availability of My-DTome is by itself a useful compendium that
reflects current and potential future drug discovery directions in
MI. We next applied different computational and statistical
methods to disentangle key global and local properties in this
network.
My-DTome:Fundamentalglobalandlocalproperties.Topological
analysis of My-DTome may offer insights into biologically relevant
connectivitypatterns,whichmaypinpointhighlyinfluentialdrugsor
targets. The distribution of My-DTome node degrees (number of
edges per node) follows a power-law distribution (Fig. 3A, power-
law exponent (c) 5 1.42, r
2 5 0.84), i.e., most nodes display a small
number of interactions, but a few of them are highly connected.
Highly connected nodes are referred to as hubs. This also indicates
thatMy-DTome interactionswerenotgeneratedatrandomandthat
they may encode clinically relevant associations. Note that if My-
DTome represented a randomly-generated network the power-law
propertywouldnothold.Figure3Billustratesthedegreedistribution
fromarandomly-generatednetworkwiththesamenumberofnodes
andedgesasMy-DTome(r
250.55).Apartfromexhibitingapower-
law property, we find that My-DTome is highly modular based on
the examination of its clustering coefficient. Its average network
clustering coefficient is larger than the average value of 10
3
randomized networks obtained by randomly shuffling the
interactions in My-DTome (0.041 vs. 0.039, P , 0.0001, single-
sample t-test).
Another fundamental property of network nodes is their capacity
to be located in the shortest communication paths between different
pairs of nodes in the network. This property defined as traffic is
measured by computing the ‘‘betweenness centrality’’ of each node
in the network (Methods). High traffic nodes are also referred to as
network bottlenecks. Different researchers, including us, have
demonstrated the potential biological relevance of high traffic nodes
with regard to their functional coordinating roles and phenotypic
Figure 1 | My-DTome generation and analysis framework.
www.nature.com/scientificreports
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10,11,12. We observe that the distribution of traffic and degree
values in My-DTome is strongly correlated (Fig. 3C). This means
that My-DTome hubs also tend to encode bottlenecks, and that they
can influence different network regions through both direct and
indirect interactions. Different network regions may underlie differ-
ent biological pathways, processes or cellular localisations, as spe-
cified below.
In My-DTome we find that the degree and traffic values of seed
drugs are strongly correlated (Fig. 3D). This also implies that a small
number of seed drugs, e.g., warfarin, exhibit dual hub-bottleneck
properties.This indicatesparticularly influential rolesforsuch drugs
on apparently unrelated targets, drugs and pathways through direct
and indirect interactions. One may argue that a strong correlation
between traffic and degree reflects a possible bias of available
information towards widely-investigated (e.g., approved) drugs in
the context of MI. However, this is not the case in My-DTome. We
note that unapproved MI drugs, as well as others not included in the
seed set, can behave as both hubs and bottlenecks (e.g., acenocou-
marol). Moreover, we find that compounds not included in the seed
set display either high degree or high traffic values. Examples of hub
compounds that are not seed drugs are: clozapine, triazolam, ginkgo
biloba, midazolam and clobazam. Drugs such as imatinib, lithium,
treprostinil, gefitinib and rifabutin exemplify My-DTome bottle-
necks, which are not MI-specified treatments. Furthermore, we find
that drug targets that are not directly linked to MI treatment (e.g.,
ABL1 and EGFR) display both high degree and high traffic values in
My-DTome.
My-DTome is a biologically-meaningful modular network. We
corroborated the modularity of My-DTome by applying a network
clustering algorithm, which have been previously shown to detect
groups of highly-connected nodes underlying specific clinical
phenotypes and responses
10,13. In My-DTome we identified a total
of 26 modules of highly-interconnected nodes with sizes ranging
from 4 (Module 17) to 319 (Module 16) nodes (Figure 4)
(Supporting Information, Dataset 2). Other very large modules are
Module 25 (277 nodes), Module 13 (245 nodes) and Module 22 (154
nodes). To estimate the potential biological relevance of these
modules, we examined each module on the basis of the
participation of its targets in specific shared biological processes,
cellular localisations, functions and pathways (Supporting
Information, Dataset 3).
Wedetectedstrongstatisticalassociationsbetweendifferentmod-
ules and Gene Ontology (GO)
14 biological processes (17 modules),
GO cellular components (16 modules) and GO molecular functions
(17 modules) (P 5 0.01, Methods). We also observed 18 modules
statisticallyenrichedbydiversebiologicalpathwaysasdefinedbythe
KEGG (Kyoto Encyclopedia of Genes and Genomes)
15. Seven mod-
ules didnotinclude proteins with statisticallydetectable associations
with these functional attributes (at P 5 0.01). Fig. 5 summarizes this
functional characterization of My-DTome modules based on the
statistically strongest associations detected. My-DTome modules
may significantly alter the normal or pathological operation of
diverse biological process ranging from RNA splicing and secretion
to wound healing and metabolism. Moreover, drugs in My-DTome
can perturb targets with coordinated functional roles in different
signalling and regulatory cascades. Many of these alterations can
be mainly driven at the extracellular level. Nevertheless, significant
functional activity can be detected in the nucleus (Module 22), dif-
ferent complexes (e.g., proteasome, Module 25) and organelles (e.g.,
autophagic vacuole, Module 11). All approved MI drugs, as well as
warfarin and aspirin, were assigned to Module 16, which shows
significant involvement in wound healing, sodium channel activity
and coagulation cascades. My-DTome proteins alsobelong todiffer-
entnetworkmodulessignificantlylinkedtomolecularpathwayswith
relevance in cancer research (e.g., Modules 22 and 23).
My-DTome encompasses evidence that the activity of (or res-
ponses to) drugs may be driven by microRNAs (miRNAs): miR-
598, miR-451, miR-133b, miR-944, miR-29a and miR-155 (Fig. 5).
This was discovered by estimating the statistical enrichment in
Figure 2 | My-DTome: A novel drug-target network in myocardial
infarction. (a) Global view. Seed drugs (green), other drugs (blue), drug
targets (orange) and other interacting proteins (grey). (b) Distribution of
seed drugs and their interacting drugs. (c) Target distribution of
My-DTome drugs.
www.nature.com/scientificreports
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Methods). There was no statistically detectable association between
miRNAs and the module containing approved MI and other key
drugs, such as warfarin and aspirin (Module 16). A significant rela-
tionship between miR-944 and Module 13, which contains the seed
drug verapamil, is observed. Despite the absence of direct strong
relationships between miRNAs and modules containing approved
MI drugs, we note that indirect miRNA-mediated regulation may
occur via inter-module interactions. For instance, various protein-
drug and drug-drug interactions occur between modules 13 and 16
(Supporting Information, Dataset 2).
The role of miR-155 in diffuse large B-cell lymphoma has been
reported
16, miR-451 has been linked to glioma cell adaptation
17 and
miR-29a can be expressed in neuronal cells
18. We did not find pub-
lished associations between miR-598 and cardiovascular disease.
Recent research has shown that miR-451 and miR-133b are dysre-
gulated in MI
19,20. The latter encourages the exploitation of
My-DTome to aid in the identification of potential new therapies
or targets in MI.
Despite these potentially interesting associations, cautious inter-
pretation is warranted as these findings relied on statistical analysis
of known miRNA bindings. Moreover, experimental testing of these
hypotheses will be required to support further assessments of poten-
tial clinical application.
Approved drugs and other compounds jointly impact diverse
clinically-relevant molecular pathways. Multiple drugs can jointly
perturb the same module-derived pathways. A more detailed
characterization of these relationships may offer a viable strategy
to explain side effects, to improve treatment effectiveness and to
explore potential drug repositioning. To demonstrate this, we
focused on the most highly altered KEGG pathways detected above
(Fig.5)andextractedallthedrugsassociatedwiththecorresponding
modules. Considering intra-module interactions only, we find that
48% of the total number of drugs included in My-DTome (351) is
linked to the complement and coagulation cascade. Calcium
signalling is shown as the second most targeted pathway (32% of
alldrugs).Theothersignificantlyimpactedpathwaysareeachlinked
to less than 5% of the My-DTome drugs (Fig. 6). Fig. 6 and
Supporting Information (Dataset 2) display a more detailed view
of (intra-module) relationships between multiple drugs and
specific molecular pathways.
Drugs of common use in MI setting: A new look at drug-drug
interactions. A closer inspection of drugs commonly applied in
the context of MI unfolds a previously unknown diversity of drug-
drug interactions. Such potentially clinically relevant associations
are inferred from either direct or indirect (including intra- and
inter-module) interactions. To illustrate this point, Fig. 7 shows
Figure 3 | Fundamental topological properties and relationships. (a) My-DTome degree value distribution. (b) Randomized network degree
distribution. (c) Relationship between traffic and degree distributions (r: correlation coefficient). (d) Relationship between traffic and degree
distributions in the seed drug set.
www.nature.com/scientificreports
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atorvastatin and verapamil. To facilitate visualisation, partial views
ofeachmodulemaybeshown(e.g.,clopidogrel).Attheintra-module
level, these drugs are associated with hundreds of drugs: aspirin,
clopidogrel and warfarin each interacting with 169 drugs in the
same module, and atorvastatin and verapamil each interacting
with 111 drugs (Supporting Information, Dataset 2). If potential
inter-module interactions are included, the possible set of drug
interactions for these two groups is increased to 240 and 238 drugs
respectively.Weobservethatthesetsofdruginteractionsareinmost
cases larger than those stored in Epocrates (https://
online.epocrates.com/home), a drug information system that is
well-known in the medical community. For example, Epocrates
Online defines 120 and 201 drug interactions for clopidogrel and
verapamil respectively. This includes its contraindicated, avoid/use
alternative, monitor/modify Tx and caution advised categories.
Also we observe partial overlaps between these and My-DTome
interactions. Nevertheless, we note that the level of commonality
between these sources is difficult to accurately estimate as
Epocrates includes diverse combinations of single compounds and
variouscommercialversionsofthesamedrug.Thesefindingsmotiv-
atefurtherinvestigationsoftheapplicationofMy-DTometosupport
patient care management.
My-DTome can also provide new perspectives to investigate
multidrug therapy. For instance, we find that clopidogrel directly
(and indirectly) interacts with drugs that alter clopidogrel respon-
siveness through competitive inhibition of CYP in the MI setting
21.
My-DTomedisplaysinter-module associationsbetween clopidogrel,
atorvastatin, itraconazole and ketoconazole (modules 13 and 16,
Supporting Information, Dataset 2), as well as an intra-module
relationship with st. John’s wort (module 16). None of these
associations were included in DrugBank as direct interactions.
Although such relationships will require stringent assessments to
estimate their clinical relevance, these observations suggest that
My-DTome may be exploited to alert clinicians about potential
adverse events.
Figure 4 | Modular organisation of My-DTome. (a) Global, modular view of My-DTome. (b)My-DTome modules depicted in isolation.
www.nature.com/scientificreports
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drugs and cardiovascular complications. We explored the
predictive capacity of My-DTome to help researchers to explain
connections between drugs not prescribed in the specific MI
setting and major, seemingly unexpected effects. To illustrate this
application, we first queried My-DTome with rosiglitazone and
celecoxib: antidiabetic and pain relief drugs respectively. Both
drugs have been reported to increase the risk of cardiovascular
complications, including myocardial infarction
22,23. Although
rosiglitazone was the only drug included in the seed set, it is not
surprising to find both drugs in My-DTome because of their
known links to MI. However, a closer look at our module-based
analysis suggests more detailed and statistically detectable
relationships not provided by either DrugBank or PharmGKB.
Rosiglitazone and celecoxib were assigned to Modules 13 and 16
respectively.
We found statistically powerful relationships between Module 13
and the regulation of the force of heart contraction (P50.001, rank:
167th), positive regulation of heart contraction (P5 5.8E-07, rank:
79th)andpositiveregulationofheartrate(P59.3E-06,rank:105th).
Ranks represent significance positions among 212 statistically
detectable associations (GO biological processes). We also found
strong perturbations in KEGG cardiovascular-specific pathways:
cardiac muscle contraction (P 5 2.54E-11, rank: 3rd among 12 stat-
istically detectable associations), dilated cardiomyopathy (P 5
1.74E-10, rank: 5th), arrhythmogenic right ventricular cardiomyo-
pathy (P 5 2.33E-10, rank: 7th) and hypertrophic cardiomyopathy
(P 5 1.99E-09, rank: 8th). Module 16 is significantly implicated in
vasoconstriction (P5 7.96E-11,ranked 8thamong 96GObiological
processperturbations),sodiumchannelactivity(P53.1E-08,ranked
1st among 36 GO molecular process perturbations), hypertrophic
cardiomyopathy (P 5 6.1E-04, ranked 7th among 15 perturbed
KEGG pathways) and arrhythmogenic right ventricular cardiomyo-
pathy (P51.6E-03, ranked 11th among 15 KEGG pathways).
As a second test, we considered non-cardiovascular drugs that
were not represented in My-DTome. We focused on fenfluramine
anddexfenfluramine,whichareappetitesuppressantsremovedfrom
the US drug market and elsewhere by 1997, but still at the centre of
legal proceedings in France
24–27. Various independent studies invol-
vingdifferentpatientpopulationshavedemonstratedtheassociation
betweenexposuretothesecompoundsandcardiovascularcomplica-
tions, such as valvular heart disease and pulmonary arterial hyper-
tension
21,26,27. Although these drugs were not explicitly included in
My-DTome,wefounddifferentinteractionroutesbetweenthemand
significant perturbations of biological processes and pathways regu-
lating heart function, remodelling and blood pressure (Fig. 8).
Figure 5 | Functional dissection of My-DTome modules. In heat map: P is the probability associated with the functional enrichment observed in each
module (Methods), colours reflect log-transformed values of P. BP: biological process, MF: molecular function, CC: cellular component. NA: No
statistically detectable association. Modules are numbered as in Fig. 4. The lighter the colour, the more significant the statistical association.
www.nature.com/scientificreports
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ferent My-DTome components: HTR1B, HTR2C, HTR2B and
SLC6A4, as well as the antidepressant drugs fluoxetine and fluvox-
amine
8. HTR1B, HTR2C and HTR2B are serotonin receptors, while
SLC6A4 is a serotonin transporter. Our module-driven My-DTome
analysis indicates that these genes are statistically associated with
positiveregulationofvasoconstriction(HTR2C),regulationofblood
vessel size (HTR2C), blood circulation (HTR2B and HTR2C), alco-
holmetabolicprocesses(HTR2C)andresponsetoethanol(HTR1B).
These proteins are assigned to My-DTome modules 13 (HTR1B,
HTR2C and HTR2B) and 16 (SLC6A4). The drugs fluoxetine and
fluvoxamine are members of Module 16. As shown above, these
modules are strongly statistically associated with specific biological
processes and alterations relevant to serious cardiovascular compli-
cations.
Discussion
Based on the integration of information from EMA, PharmaGKB,
DrugBank and other public databases, we investigated different
network biology methods and tools to contribute: a. My-DTome, a
drug-target interaction resource that will assist future translational
research in MI, b. new theoretical and clinical insights into the drug-
target interaction landscape of MI, c. novel associations between
drugs, targets and critical networks with potential clinical value.
Figure 6 | Relationships between multiple drugs and specific KEGG pathways. (a) Distribution of numbers of drug-pathway relationships. SP:
spliceosome, COL: colorectal cancer, END: endocytosis, ERB: ErbB signalling pathway, ABC: ABC transporters, AUT: regulation of autophagy, NEU:
neuroactiveligand-receptorinteraction,CAL:calciumsignallingpathway,COA:complementandcoagulationcascades,MET:purinemetabolism,MTO:
mTOR signalling pathway, CAN: pathways in cancer, SLC: small cell lung cancer, PROT: proteasome. From (b) to (f), examples of multiple drugs-
pathway interactions: CAL, COA, ERB, MTO and AUT pathways.
www.nature.com/scientificreports
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My-DTome nodes on the basis of topological analysis and the detec-
tion of highly perturbed molecular pathways. Apparently unrelated
drugs can display comparable network connectivity and functional
features as those shown by seed drugs. Our analyses show that most
drugs directly perturb calcium signalling and coagulation cascades.
This suggests, first, that most known and potentially novel com-
pounds affect clinically-relevant molecular pathways. The finding
that the vast majority of these compounds target only two pathways,
among the large number of biological pathways involved in the
occurrence and outcome of MI, suggests that there is still room to
design new drugs targeting so far unexplored pathways. Secondly,
this may provide new research routes with regard to novel applica-
tion of compounds not yet investigated in the specific MI context.
This allowed us to characterize connections between non-cardio-
vascular drugs (rosiglitazone, celecoxib and fenfluramine) and
major,unwanted cardiovascular effects. Thirdly,it reveals new levels
of complexity and activity at a systems-level not formulated prior to
this investigation. By data mining My-DTome, we identified several
miRNAs that are known and yet-to-be investigated potential novel
therapeutic targets for MI treatment. Experimental validation of
these associations will be required to further estimate their potential
clinical value.
Although our results may be constrained by data incompleteness,
they are based on high quality drug and protein interaction annota-
tions. Moreover, the reported modularity-based associations
represent statistically detectable patterns. Future My-DTome ana-
lyses should directly address the level of ambiguity associated with
Figure 7 | Visualisation of intra-module interactions between selected drugs of common use in MI setting, other compounds and their targets. From
(a) to (d): aspirin, atorvastatin and verapamil, clopidogrel and warfarin respectively. To facilitate visualisation, partial views of each module may be
shown (e.g., clopidogrel’s module).
www.nature.com/scientificreports
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nature of drug-drug interactions, e.g., interaction types and descrip-
tionofsupportingevidence.Suchataskwillnaturallybeconstrained
by the availability of this type of information in the original sources.
Our My-DTome investigation supports the notion of applying
system-based approaches to elucidating drug and target interactions
in the MI context. The prevailing approach based on descriptive
views of approved drugs and their interactions cannot adequately
characterize the complexity of the therapeutic panorama in MI. This
implies reduced opportunities to anticipate unwanted effects and
potential novel treatments. We expect new research directions to
further address network-driven complexity and therapeutic impact.
In the long-term, this will open new possibilities for a more perso-
nalised treatment of MI.
Methods
Drugandproteininteractiondatabases.WeobtainedtheseeddrugsfromtheEMA
(http://www.ema.europa.eu) and PharmGKB (8) databases (as of 8 December 2010).
Weconsidereddrugsincludedinthecategoryof‘‘myocardial infarction’’only.Drug-
druganddrug-target interactionsweredownloadedfromDrugBank
9.Target-protein
interactions were obtained by integrating experimentally validated interactions in
humans from the DIP
28,IntAct
29 and MINT
30 databases. Weused them because their
good interactome coverage, complementarity and low-error have been
demonstrated
31. We concentrated on immediate direct interactions. All My-DTome
associations are available in the Supporting Information (Dataset 1).
Network features and topological analysis. The degree of a node is the number of
edgesassociatedwithanode.Nodetrafficisthetotalnumberofshortestpathsthatgo
through thenode, andwhichconnect anytwoothernodes inthe network.Therefore,
hightrafficnodescanrepresent‘‘cross-communication’’hotspotsor‘‘bottlenecks’’ in
the network. The clustering coefficient measures (from 0 to 1) the level of
interconnectivity around a node. A node at the centre of a fully-connected sub-
network will display a clustering coefficient equal to 1. A network with a higher
average clustering coefficient suggests the existence of network modularity. For
network comparisons, randomized networks were obtained by randomly shuffling
the edges of My-DTome, while keeping unchanged its total number of nodes. My-
DTome follows a power-law degree distribution of the form: D(k),k
2c, k represents
the degree values, D(k) is the frequency of nodes with degree k, c is the power-law
exponent and , represents proportionality. On a logarithmic scale, c represents the
slope of the line fitted to this distribution (Results).
Module identification and characterization. We identified network modules with a
‘‘greedy’’ network clustering algorithm
13. This algorithm searches for sub-networks
with highly-connected nodes, and the outcome is the partition of the network into a
set of disjoint modules that optimize a ‘‘modularity score’’, Q. Q computes the
numberofedgesobservedinaputativemoduleinrelationtothenumberofedgesthat
would be obtained by chance, i.e., by randomly pairing the proteins in the putative
module. This algorithm has been applied to detect disease-related modules in
different network biology investigations
10,13. Statistical associations between modules
and functional annotations (GO terms, KEGG pathways and miRNA targets) were
estimatedby finding over-representation of annotationsin the modulesin relation to
theother genes inthe human genome. Thisisdone byrunning Fisher’s exacttestsfor
232contingency tables,followedbythe (Benjamini &Hochberg method)correction
of the P values to account for multiple-hypothesis testing. We concentrated on the
analysis of associations with (corrected) P 5 0.01 or lower values. miRNA-target
associations were mined from miRBase
32.
Figure 8 | My-DTome predicts unexpected cardiovascular side effects of appetite suppressants fenfluramine and dexfenfluramine.
www.nature.com/scientificreports
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33
and Polar Mapper
13. Module identification and traffic value estimation were
computed with Polar Mapper
13. Other topological analyses were implemented with
Cytoscape plug-ins: NetworkAnalyzer
34 and the Random Network plugin
35.W e
conducted functional characterization of modules with the Fatigo tool, under the
Babelomics (v4.1) platform
36. Other statistical analyses were done with the Statistica
package
37.
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